



VIA HAND DELIVERY OCTOBER 28, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
He et al.

Docket No.: PF140C2

Application No.: 09/895,263

Group Art Unit: 1653

Filed: July 2, 2001

Examiner: G. Bugaisky

For: Interleukin-1, Beta Converting Enzyme Like  
Apoptosis Protease-3 and 4

RECEIVED

OCT 31 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, DC 20231

Dear Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorney for Applicants hereby directs the Examiner's attention to references AA-CH listed on the attached Form PTO/SB/08.

Copies of references AA-CH were submitted by Applicants or cited by the Examiner in connection with United States Patent Application Serial No. 08/334,251, filed November 1, 1994, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the file of United States Patent Application Serial No. 08/334,251 for copies of references AA-CH.

The listed references are presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. § 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed references of record in the file history of the application and consider the information contained therein during the prosecution of this application.


Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants

do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(b), Applicants believe that this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits. Accordingly, no fee is believed due. However, should the Patent Office determine otherwise, please charge the required fee to our Deposit Account No. 08-3425.

Dated: October 28, 2002

Respectfully submitted,

By 

Lin J. Hymel

Registration No.: 45,414

HUMAN GENOME SCIENCES, INC.

9410 Key West Avenue

Rockville, Maryland 20850

(301) 251-6015

Attorney for Applicant

KKH/LJH/LT/ba